Nurix Therapeutics price target lowered to $21 from $22 at Wells Fargo

Wells Fargo lowered the firm’s price target on Nurix Therapeutics (NRIX) to $21 from $22 and keeps an Overweight rating on the shares. The firm thinks the clarity on bexdeg’s 3L+ CLL pivotal trial dose plus concurrent financing removes key overhangs. With the company funded into 2028, read through from Kymera Therapeutics’ (KYMR) upcoming KT-621 Phase 1b data and a potential GILD IRAK4 opt-in decision in 2026, Wells likes the setup.